Literature DB >> 31471057

Medical Management of Cushing Disease.

Nicholas A Tritos1, Beverly M K Biller2.   

Abstract

Medical therapy for Cushing disease is primarily used to control hypercortisolism in patients whose disease persists or with recurrent disease after pituitary surgery, including those awaiting the salutary effects of radiation therapy. In can also be used to control hypercortisolism preoperatively, and in patients who decline surgery or whose tumor location is unknown. Steroidogenesis inhibitors, centrally acting agents, and glucocorticoid receptor antagonists are currently available to treat hypercortisolism, and several novel agents are in development. Given the absence of head-to-head clinical trials, choice between treatments has to be individualized based on careful consideration of patient, tumor, and disease characteristics.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cabergoline; Cushing disease; Etomidate; Ketoconazole; Levoketoconazole; Metyrapone; Mifepristone; Mitotane

Mesh:

Substances:

Year:  2019        PMID: 31471057     DOI: 10.1016/j.nec.2019.05.007

Source DB:  PubMed          Journal:  Neurosurg Clin N Am        ISSN: 1042-3680            Impact factor:   2.509


  5 in total

1.  Efficacy and safety of pasireotide for Cushing's disease: A protocol for systematic review and meta-analysis.

Authors:  Nairui Zhao; Xinxin Yang; Cuiliu Li; Jie Ma; Xiuping Yin
Journal:  Medicine (Baltimore)       Date:  2020-12-18       Impact factor: 1.817

2.  Central serous chorioretinopathy in active endogenous Cushing's syndrome.

Authors:  Joost Brinks; Femke M van Haalen; Thomas J van Rijssen; Nienke R Biermasz; Onno C Meijer; Alberto M Pereira; Camiel J F Boon; Elon H C van Dijk
Journal:  Sci Rep       Date:  2021-02-02       Impact factor: 4.379

Review 3.  Targeting Aggressive Pituitary Adenomas at the Molecular Level-A Review.

Authors:  Benjamin Voellger; Zhuo Zhang; Julia Benzel; Junwen Wang; Ting Lei; Christopher Nimsky; Jörg-Walter Bartsch
Journal:  J Clin Med       Date:  2021-12-27       Impact factor: 4.241

Review 4.  Pharmacological management of severe Cushing's syndrome: the role of etomidate.

Authors:  Andrea Pence; Megan McGrath; Stephanie L Lee; Douglas E Raines
Journal:  Ther Adv Endocrinol Metab       Date:  2022-02-14       Impact factor: 3.565

5.  Mifepristone Increases Life Span in Female Drosophila Without Detectable Antibacterial Activity.

Authors:  Gary N Landis; Luke Riggan; Hans S Bell; William Vu; Tianyi Wang; Ina Wang; Felicia I Tejawinata; Sebastian Ko; John Tower
Journal:  Front Aging       Date:  2022-07-22
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.